MOLECULIN BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.08 USD | +0.99% |
|
+6.72% | -60.55% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Moleculin Biotech I...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.08
USD
Average target price
35
USD
Spread / Average Target
+588.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.55% | 11.32M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -2.74% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- MBRX Stock
- News Moleculin Biotech, Inc.
- Transcript : Moleculin Biotech, Inc., Q3 2022 Earnings Call, Nov 10, 2022
